Dominari Holdings Inc. annual report, FY2012

Business context and reporting period

Filing identity differs from request metadata: the supplied filing is Spherix Incorporated’s Form 10-K, not a Dominari Holdings Inc. filing. It covers the fiscal year ended December 31, 2012, rather than a standalone fourth quarter; the text does not provide a clear Q4 income statement.

Spherix sold its consulting subsidiary on December 3, 2012, for nominal consideration, leaving biotechnology research and development as its sole business at year-end. The company was reviewing strategic alternatives and deferring substantial investment in its biotech activities.

Financial results and position

Continuing-operations R&D expense fell to $727,091 from $1.65 million, reflecting completion of SPX106T preclinical studies. SG&A rose to $2.76 million from $2.55 million. The consulting business, reported as discontinued operations, had revenue of $728,312 versus $820,925 and a loss of $968,991 versus $383,529. No meaningful operating margin is indicated by the minimal continuing revenue and operating loss.

Material changes and unusual items

• Management concluded in February 2013 that prior financial statements dating back to mid-November 2009 should not be relied upon because warrants had been incorrectly classified as equity rather than liabilities. The 2011 statements were restated. The filing says these non-cash adjustments did not change reported cash, total assets, revenue, or cash flows.
• Warrant fair-value changes produced $1.20 million of other income in 2012, versus $3.72 million in 2011; 2012 also recorded a $621,983 loss on warrant issuance. These non-cash items materially affected reported earnings.
• The company raised approximately $2.3 million net in a November 2012 private placement. In March 2013, investors exchanged warrants covering 474,266 shares for 229,337 shares of convertible Series C preferred stock.
• Common stockholders’ equity was below NASDAQ’s $2.5 million continued-listing threshold at year-end. The company reported that a March 2013 warrant exchange increased equity by approximately $2.7 million.

Outlook, risks and contingencies

Management said year-end cash was expected to fund reduced operations for the next 12 months, including $475,000 of severance payments due in the first half of 2013. It also said existing capital was inadequate for pursuing acquisitions and that further financing might be needed. The filing warns that failure to raise funds could force the company to cease operations or dissolve.

The company did not expect material R&D spending in 2013 and was seeking buyers, licensees, or partners for Biospherics; it acknowledged a buyer might not be found and that inventory disposal could incur costs. D-tagatose patents had expired, and SPX106T had only reached animal studies; no clinical trials were then underway.

In February 2013, subsidiary Nuta signed a non-binding letter of intent to acquire a wireless-patent company for 12 million Spherix common shares, with Nuta to have at least $2 million cash at closing. Completion remained subject to due diligence, shareholder approval, and definitive agreements; no assurance was given that the deal would close or succeed. Other key risks include potential dilution, volatile and thinly traded shares, NASDAQ compliance, regulatory and development uncertainty, and reliance on third parties and licensed technology.

Management reported ineffective disclosure controls and internal control over financial reporting at December 31, 2012, due to a material weakness involving warrant accounting. The auditor gave an unqualified opinion on the financial statements but did not attest to internal control effectiveness.

Important facts for investors to verify

• Confirm the issuer and reporting period: this is Spherix Incorporated’s FY 2012 10-K, not a Dominari Holdings filing or a standalone Q4 report.
• Review the warrant restatement, the related liability valuation assumptions, and whether the previously filed affected-period reports were corrected as described.
• Check current cash runway, severance and lease obligations, and financing needs against management’s 12-month liquidity assessment.
• Verify the March 2013 preferred-stock exchange, resulting equity and NASDAQ listing compliance, and potential dilution from outstanding securities.
• Track the wireless-patent acquisition’s status, required shareholder approval, share issuance, cash funding, and final transaction terms.
• Assess remediation of the disclosed material weakness and progress on any Biospherics sale, license, partnership, or wind-down.